|
|
 |
| |
CEO's Letter - Introduction |
THE ACTELION ANNUAL REPORT 2004 |
|
|
|
| |
|
|
|
|
|
|
| People are the driving force of our success |
| |
Actelion’s momentum in markets across the globe continued to accelerate in 2004. Net revenue rose 53% to CHF 471.9 million over the previous year, powered by a 50% surge in sales of Tracleer®. Three years after launch, this breakthrough oral therapy has already become the cornerstone treatment in pulmonary arterial hypertension (PAH), with untapped potential in related indications. Our second product on the market, Zavesca®, an oral therapy for lipid-storage disorders, rose to CHF 6.1 million, impressive in view of its currently restricted label. While the termination of our tezosentan trial in acute heart failure represented a setback, other compounds in development have moved forward to take its place, illustrating the strength of our pipeline. Our net income of CHF 87.2 million, compared to a net loss of CHF 9.9 million in 2003, is a remarkable achievement for a company established only seven years ago.
The unique culture of Actelion was at the forefront in 2004 as we continued to push the envelope of innovation in the laboratories, in terms of the professional execution of our clinical trials, new marketing and sales initiatives, and in view of the consolidation of the core values that are behind our drive and enthusiasm.
|
|
|
|
